A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
Condition: Uterine Serous Carcinoma
MeSH terms: Carcinoma; Cystadenocarcinoma, Serous
Intervention: Adavosertib
Intervention description: The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
Intervention MeSH terms: Adavosertib
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 109.0
Sex: Female
Minimum age: 18 Years
Maximum age: 130 Years
Healthy volunteers: No
Keywords: Adavosertib; Phase 2b; open-label; single-arm

Summary:

      This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of
      the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma
      (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for
      the management of USC.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Subjects must be aged ≥ 18 years of age inclusive, at the time of signing the informed
             consent.

          2. Histologically confirmed recurrent or persistent USC. Subjects with carcinosarcomas
             are not eligible.

          3. Evidence of measurable disease as per RECIST v1.1.

          4. At least 1 prior platinum-based chemotherapy regimen for the management of USC. Prior
             receipt of immune checkpoint inhibitors, vascular endothelial growth factor (VEGF)
             inhibitors and human epidermal growth factor receptor 2 (HER2) targeted therapy is
             allowed. There is no restriction on the number of prior lines of systemic therapy.

          5. Eastern Cooperative Oncology Group performance (ECOG) status 0-1.

          6. Life expectancy ≥ 12 weeks.

          7. Subjects must have normal organ and marrow function at baseline, within 7 days prior
             to study drug administration.

          8. Consent to submit and provide a mandatory Formalin-fixed paraffin-embedded tumor
             sample for central testing.

          9. Female subjects who are not of childbearing potential and women of childbearing
             potential who agree to use adequate contraceptive measures.

        Exclusion Criteria:

          1. Any underlying medical condition and uncontrolled intercurrent illness that would
             impair the ability of the subject to receive study treatment, as judged by the
             investigator.

          2. With the exception of alopecia, any unresolved toxicities from prior therapy greater
             than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of
             starting study treatment.

          3. Unable to swallow oral medications.

          4. Spinal cord compression or metastases unless asymptomatic, stable, and not requiring
             steroids for at least 4 weeks prior to start of study intervention.

          5. Subjects with current signs or symptoms of bowel obstruction, including sub-occlusive
             disease, related to underlying disease.

          6. Any of the following cardiac diseases currently or within the last 6 months:

               -  Unstable angina pectoris

               -  Acute myocardial infarction

               -  Congestive heart failure

               -  Conduction abnormality not controlled with pacemaker or medication

               -  Significant ventricular or supraventricular arrhythmias

          7. History of Torsades de pointes unless all risk factors that contributed to Torsades
             have been corrected.

          8. a) Resting corrected QTc interval using the Fridericia formula (QTcF) > 480 msec, or
             b) congenital long QT syndrome.

          9. Immunocompromised subjects.

         10. Subjects with known active hepatitis (ie, hepatitis B or C).

         11. Prior treatment with any of the following:

               -  Cell cycle checkpoint inhibitor.

               -  Anticancer treatment drug ≤ 21 days (≤ 6 weeks for nitrosoureas or mitomycin C)
                  or use of an investigational product within 5 half-lives prior to the first dose
                  of adavosertib. For Programmed cell death-1 receptor (PD-1) /Programmed
                  death-ligand 1 (PD-L1) inhibitors, a minimum of 28 days since last dose is
                  required.

               -  Prescription or non-prescription drugs known as moderate to strong inhibitors /
                  inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment.

               -  Herbal medications 7 days prior to first dose of study treatment.

         12. Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide
             field of radiation within 4 weeks prior to the first dose of study intervention.

         13. Major surgical procedures ≤ 28 days, or minor surgical procedures ≤ 7 days, prior to
             beginning study.

         14. Subjects with a known hypersensitivity or contraindication to adavosertib or any of
             the excipients of the product.

         15. Currently pregnant or breast-feeding.